Compare DraftKings Inc (DKNG) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DraftKings Inc vs Regeneron Pharmaceuticals Inc — how do they compare? DraftKings Inc trades at $25.16 (market cap $12.51B), while Regeneron Pharmaceuticals Inc trades at $653.1 (market cap $68.79B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 5.5× DraftKings Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.57% dividend while DraftKings Inc pays none. Which is the better fit depends on your goals.
| DKNG | REGN | |
|---|---|---|
Market Cap | $12.51B | $68.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $48.23 | $812.27 |
52-Week Low | $20.72 | $542.52 |
Enterprise Value | $13.43B | $62.74B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DraftKings (DKNG) trades at $26.45, showing minimal daily movement. The stock exhibits a bullish technical trend with strong moving average signals, supported by a positive cash flow turnaround to $274.40 million in 2025. Revenue growth has been robust, rising from $2.2 billion in 2022 to $6.05 billion in 2025, with the company achieving its first net profit of $3.71 million. Recent expansion into Alberta and the launch of prediction markets highlight ongoing growth initiatives.
The outlook is positive, driven by analyst consensus with a $34.18 price target and 73% buy ratings. Key catalysts include upcoming sports events and product launches, but risks involve high valuation multiples and regulatory scrutiny. Profitability remains nascent, requiring sustained execution to justify current premiums.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
